These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 4083040)

  • 1. Acetohydroxamate, a urease inhibitor, inhibits the covalent binding reaction of complement proteins C3 and C4.
    Sim E; Jones A; Stanley L
    Acta Pharmacol Toxicol (Copenh); 1985 Oct; 57(4):304-6. PubMed ID: 4083040
    [No Abstract]   [Full Text] [Related]  

  • 2. Suppression of Fc Receptor and C4.C3 receptors of the granulocytes from patients with systemic lupus erythematosus.
    Shingu M; Todoroki T; Sakai K; Nobunaga M
    J Rheumatol; 1981; 8(6):910-6. PubMed ID: 7328566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A; Barr SG; Magder LS; Petri M
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypercatabolism of C3 and C4 in active and inactive systemic lupus erythematosus.
    Charlesworth JA; Peake PW; Golding J; Mackie JD; Pussell BA; Timmermans V; Wakefield D
    Ann Rheum Dis; 1989 Feb; 48(2):153-9. PubMed ID: 2784659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiphospholipid Antibodies are Associated with Low Levels of Complement C3 and C4 in Patients with Systemic Lupus Erythematosus.
    Garabet L; Gilboe IM; Mowinckel MC; Jacobsen AF; Mollnes TE; Sandset PM; Jacobsen EM
    Scand J Immunol; 2016 Aug; 84(2):95-9. PubMed ID: 27135178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased amounts of C4-containing immune complexes and inefficient activation of C3 and the terminal complement pathway in a patient with homozygous C2 deficiency and systemic lupus erythematosus.
    Garred P; Mollnes TE; Thorsteinsson L; Erlendsson K; Steinsson K
    Scand J Immunol; 1990 Jan; 31(1):59-64. PubMed ID: 2300790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C4-binding protein in sera of patients with systemic lupus erythematosus and mixed essential cryoglobulinemia.
    Schifferli JA; Bakkaloglu A; Amos N; Peters DK
    Complement; 1984; 1(2):81-6. PubMed ID: 6544184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo metabolism of the third component of complement in systemic lupus erythematosus.
    Petz LD; Powers R; Fries JR; Cooper NR; Holman HR
    Arthritis Rheum; 1977; 20(7):1304-13. PubMed ID: 303101
    [No Abstract]   [Full Text] [Related]  

  • 9. The covalent binding reaction of C3 and C4.
    Law SK
    Ann N Y Acad Sci; 1983; 421():246-58. PubMed ID: 6586101
    [No Abstract]   [Full Text] [Related]  

  • 10. CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.
    Wilson JG; Andriopoulos NA; Fearon DT
    Immunol Res; 1987; 6(3):192-209. PubMed ID: 2960763
    [No Abstract]   [Full Text] [Related]  

  • 11. Autolytic fragmentation of complement components C3 and C4 and its relationship to covalent binding activity.
    Sim RB; Sim E
    Ann N Y Acad Sci; 1983; 421():259-76. PubMed ID: 6202197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of the determination of C3d and the hemolytic activity of C4 (C4H) during systemic lupus erythematosus].
    Santoro F; Vanhille P; Duquesnoy B; Raviari B; Wattré P; Lemaitre V; Siame JL; Hatron PY
    Rev Med Interne; 1980; 1(1):21-7. PubMed ID: 6972075
    [No Abstract]   [Full Text] [Related]  

  • 13. The complex nature of serum C3 and C4 as biomarkers of lupus renal flare.
    Birmingham DJ; Irshaid F; Nagaraja HN; Zou X; Tsao BP; Wu H; Yu CY; Hebert LA; Rovin BH
    Lupus; 2010 Oct; 19(11):1272-80. PubMed ID: 20605879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The third (C3) and the fourth (C4) components of complement: labile binding site and covalent bond formation.
    Janatova J
    Ann N Y Acad Sci; 1983; 421():218-34. PubMed ID: 6586100
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunoglobulin and complement deposits in lupus glomerulonephritis.
    Méry JP; Morel-Maroger L; Boelaert J
    Proc Eur Dial Transplant Assoc; 1975; 11():506-11. PubMed ID: 1197274
    [No Abstract]   [Full Text] [Related]  

  • 16. Influence of macrophage activation on the synthesis of complement components C2, C3, C4.
    Hartung HP; Zanker B; Bitter-Suermann D
    Adv Exp Med Biol; 1982; 155():525-9. PubMed ID: 7158498
    [No Abstract]   [Full Text] [Related]  

  • 17. Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus.
    Raymond W; Eilertsen G; Nossent J
    J Immunol Res; 2018; 2018():8051972. PubMed ID: 30687766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The internal thioester and the covalent binding properties of the complement proteins C3 and C4.
    Law SK; Dodds AW
    Protein Sci; 1997 Feb; 6(2):263-74. PubMed ID: 9041627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydralazine and isoniazid reduce the formation of soluble immune complexes by complement.
    Schifferli JA
    Immunol Lett; 1985; 9(5):297-9. PubMed ID: 3997205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; Hermans J; van Es LA; Cats A
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.